Telescope Innovations Delivers Continued Strong Sales Revenue Growth in First Fiscal Quarter 2026
Rhea-AI Summary
Telescope Innovations (OTCQB: TELIF) reported Q1 fiscal 2026 results for the quarter ended Nov 30, 2025: revenues CAD $2.70M (Q1 FY2025: $1.20M) and an adjusted EBITA loss CAD $0.83M (Q1 FY2025: loss $0.10M). Revenue growth was driven by DirectInject-LC product sales, Contract Research Services and delivery of the first Self Driving Laboratory to KPBMA.
Expenses rose as the company invested in hiring, parts, travel and professional services. Telescope closed a $6.50M capital raise and received conditional government funding of $3.60M for lithium recycling and solid-state battery work.
Positive
- Revenue increased to CAD $2.70M (Q1 FY2025: $1.20M)
- Contract Research Services rose to CAD $0.82M (Q1 FY2025: $0.38M)
- Completed final tranche of equity financing, totaling a $6.50M capital raise
- Received conditional government support of $3.60M for lithium and battery initiatives
- Delivered first Self Driving Laboratory (SDL) to KPBMA and advanced ReCRFT to >99.9% Li2CO3 purity
Negative
- Operating expenses increased to CAD $3.92M (Q1 FY2025: $1.55M)
- Adjusted EBITA loss widened to CAD $0.83M (Q1 FY2025: loss $0.10M)
News Market Reaction – TELIF
In the Feb 2 session, TELIF gained 0.41%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE:J4U) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended November 30, 2025 (Q1). The Company generated revenues of
FINANCIAL HIGHLIGHTS OF THE FISCAL QUARTER ENDED NOVEMBER 30, 2025
All values are represented in CAD.
- Revenues of
$2.70M M (versus$1.20M M in Q1 FY2025) - Expenses of
$3.92M M (versus$1.55M M in Q1 FY2025) - Adjusted EBITA loss of
$0.83M M (versus a loss of$0.10M M in FY2025)
OPERATIONAL HIGHLIGHTS
- Record Quarterly Revenue driven by:
- Delivery of the first Self Driving Laboratory (SDL) to the Korean Pharmaceutical BioPharmaceutical Manufacturers' Association (KPBMA).
- DirectInject-LC™ Product Sales.
- Contract Research Services (
$0.82M M vs$0.38M M in Q1 FY2025).
- Expenses grew in for the fiscal quarter ended November 30, 2025 (Q1) associated with:
- Consulting and Salary Costs associated with hiring of technical, sales and research to support rapid growth in the business.
- Parts Expense and associated Travel Expenses related to product sales, product fulfillment (installation and training) and general sales activity.
- Professional Services and Management Fees for private placement advisory, audit, legal fee accruals and one-time performance payment.
- Appointed Vaso Vlachos as Chief Operation Officer.
- Final Tranche of Equity Financing wrapped up to complete
$6.50M M capital raise. - Demonstrated proprietary ReCRFT™ process achieved >
99.9% pure Li2CO3 from Battery Recycling Brines. The recycled materials have been shipped to Cellmine Ltd. (UK), a next generation battery recycling company and the University of St. Andrews (UK) for fabrication and testing in Li-Ion Batteries. - Received conditional approval for
$3.60M M in government funding for the development, demonstration, and scale-up of Lithium recycling and Solid-State Battery materials technologies from National Research Council of Canada - Industrial Research Assistance Program (NRC-IRAP) and Natural Resources of Canada (NRCan) - Critical Minerals Research, Development and Demonstration Program.
"Our Q1 results position Telescope firmly on track to achieve our technical, strategic and financial targets for the year," commented Henry Dubina, Telescope CEO. "The combination of strong product sales, and groundbreaking collaborations such as our work with Pfizer on Self-Driving Labs, plus the advancement of proprietary technologies such as ReCRFT™, highlights our ability to deliver value across multiple industries. As we continue to scale operations and reinvest in growth, we remain confident in our capacity to drive innovation and sustain our momentum throughout 2026."
Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the quarter ended November 30th, 2025, both of which are available under the profile for the Company on SEDAR+ (www.sedarplus.ca).
About Telescope Innovations
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
On behalf of the Board,
Telescope Innovations Corp.
Henry Dubina, Chief Executive Officer
E: henry.dubina@telescopeinn.com
778-262-1166
Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information.
Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with general economic conditions; adverse industry events; the Company's ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of the Company to implement its business strategies; competition; and other assumptions, risks and uncertainties.
Forward-looking statements in this document include expectations surrounding the Company's financial position, the momentum of the DirectInject-LC™ product, the Company's strategic partnerships within the pharmaceutical and chemical manufacturing sector and all other statements that are not statements of historical fact.
The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
The CSE has neither approved nor disapproved of the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282288